Shire PLC (LON:SHP)‘s stock had its “overweight” rating reiterated by equities research analysts at JPMorgan Chase & Co. in a report issued on Tuesday. They currently have a GBX 6,000 ($74.10) target price on the biopharmaceutical company’s stock. JPMorgan Chase & Co.’s price objective suggests a potential upside of 26.08% from the stock’s previous close.
Several other equities research analysts also recently weighed in on SHP. Royal Bank of Canada reaffirmed an “outperform” rating on shares of Shire PLC in a research note on Monday. BNP Paribas reaffirmed an “outperform” rating and set a GBX 5,900 ($72.87) target price on shares of Shire PLC in a research note on Monday, February 27th. HSBC Holdings plc upped their target price on shares of Shire PLC from GBX 4,500 ($55.58) to GBX 4,550 ($56.19) and gave the stock a “hold” rating in a research note on Tuesday, February 21st. Jefferies Group LLC reaffirmed a “buy” rating and set a GBX 6,600 ($81.51) target price on shares of Shire PLC in a research note on Friday, February 17th. Finally, Liberum Capital reaffirmed a “buy” rating and set a GBX 5,500 ($67.93) target price on shares of Shire PLC in a research note on Thursday, December 22nd. One investment analyst has rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of GBX 6,115.60 ($75.53).
Shares of Shire PLC (LON:SHP) opened at 4759.00 on Tuesday. The firm’s market capitalization is GBX 42.96 billion. The stock’s 50 day moving average is GBX 4,742.35 and its 200 day moving average is GBX 4,766.87. Shire PLC has a 1-year low of GBX 2,707.19 and a 1-year high of GBX 5,377.00.
The company also recently disclosed a dividend, which will be paid on Tuesday, April 25th. Shareholders of record on Thursday, March 9th will be given a GBX 20.64 ($0.25) dividend. The ex-dividend date of this dividend is Thursday, March 9th. This is an increase from Shire PLC’s previous dividend of $3.51. This represents a dividend yield of 0.43%.
Your IP Address:
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
This story was originally published by WKRB News (http://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://www.wkrb13.com/markets/2024410/shire-plc-shp-stock-rating-reaffirmed-by-jpmorgan-chase-co.html
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.